The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.

Author(s): Baiza-Duran LM, Alvarez-Delgado J, Contreras-Rubio AY, Medrano-Palafox J, De Luca-Brown A, Casab-Rueda H, Cortes-Gastelum MA, Garciduenas-Mejia MJ, Gomez-Bastar P, Gil-Carrasco F, Hartleben-Matkin C, Jimenez-Roman J, Moreno-Marin ML, Paczka-Zapata JA, Velasco-Gallegos G, Vergara-Sinta M

Affiliation(s): Clinical Research Department, Laboratorios Sophia, S.A. de C.V. Guadalajara, Jalisco, Mexico. drbvista@sophia.com.mx

Publication date & source: 2009-09, Ann Ophthalmol (Skokie)., 41(3-4):174-8.

Publication type: Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.